A Chicago jury rejected an Illinois woman’s claim that the discontinued heartburn drug Zantac caused her colon cancer. This case is the first of thousands of similar lawsuits. The jury in Cook County, Illinois, found that Angela Valadez, an 89-year-old Illinois resident, did not prove her cancer was linked to her Zantac use. Related: GSK Concealed Risk Associated With Discontinued Heart Burn Drug Zantac, Whistleblower Lawsuit Claims. Valadez alleged that her cancer resulted from taking over-the-
GSK Plc (NYSE:GSK) has been reportedly sued by an independent Connecticut laboratory, Valisure, accusing the pharmaceutical giant of defrauding the U.S. government and taxpayers by concealing cancer risks associated with Zantac, once a blockbuster heartburn drug. Related: Pfizer Agrees To Settle Over 10,000 Lawsuits About Cancer Risks Associated With Discontinued Heartburn Drug Zantac. In a whistleblower complaint filed on Monday, Valisure claimed GSK violated the federal False Claims Act by hid
Tuesday, GSK plc (NYSE:GSK) released headline results from the phase III clinical trials SWIFT-1 and SWIFT-2, which assessed the efficacy and safety of depemokimab versus placebo in adults and adolescents with severe asthma with type 2 inflammation characterized by blood eosinophil count. Earlier this year, GSK acquired Aiolos Bio Inc., a privately held asthma drug maker, for $1 billion. Both SWIFT-1 and SWIFT-2 met their primary endpoints of a reduction in the annualized rate of clinically sign